SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
NEW YORK, Oct. 03, 2016 -- EMBER THERAPEUTICS (OTCQB:EMBT), today announced that Olympic Gold Medalist Ryan Lochte has signed an endorsement agreement with the company. Lochte, one of the stars of Team USA, has won 12 Olympic medals, including six gold medals, three silver medals and three bronze medals making him one of the most decorated swimmers in Olympic history.
The University of Florida graduate swam his way to victory countless times as a member of the Florida Gators swimming team, and was named NCAA Swimmer of the Year twice. He also became a seven-time NCAA champion, a seven-time SEC champion and a 24-time All-American. Lochte, who was born in Rochester New York, is currently a contestant on the Emmy nominated Dancing with the Stars.
“Ember Therapeutics’ Migralex is one of the top names in over the counter pain and headache relief and I’m thrilled to be in partnership with them,” said Lochte.
“Ryan Lochte has had an outstanding athletic career,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc., “We are honored to have him be our spokesperson for Migralex, the only over the counter pain medicine containing Magnesium, which is easier on the stomach and further enhances the drug’s ability to deal with difficult headaches and most types of pain.”
As a result of over 25 years of research, a world renowned neurologist has developed and patented a breakthrough headache medicine that has been clinically proven to be highly effective in relieving most types of pain, including arthritis pain, tension headaches, sinus headaches, stress headaches, menstrual headaches, and various other pains.
Migralex™ is a patented product and is the strongest combination pain medicine available without a prescription. Its special rapid release formula gives fast acting relief, and is gentle on the stomach. Migralex™ reduces side effects common with other OTC pain relievers. It contains no caffeine, sodium or preservatives, and contains magnesium as a buffering agent.
Migralex™ is currently available at CVS, local pharmacies, online at Amazon.com and the product website www.migralex.com. To learn more about Migralex™ please access www.migralex.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has several commercial stage products and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
Contact Information: Betty Rose (investors) (646) 406-6243 [email protected]
